{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:47:02Z","timestamp":1793213222624,"version":"4.5.0"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Imaging Biol"],"DOI":"10.1007\/s11307-026-02122-8","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T13:52:25Z","timestamp":1785505945000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Toward a Structured Imaging Reporting System for Kidney Masses: The Molecular Imaging Perspective on KI-RADS"],"prefix":"10.1007","author":[{"given":"Wonkyu P.","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Zobaer","family":"Islam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis J.","family":"Mazzarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilja B.","family":"Solnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Shuch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin L.","family":"Viglianti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Repka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asim","family":"Afaq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf A.","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Gorin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven P.","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"issue":"18","key":"2122_CR1","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1093\/jnci\/djj362","volume":"98","author":"JM Hollingsworth","year":"2006","unstructured":"Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK (2006) Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst 98(18):1331\u20131334","journal-title":"J Natl Cancer Inst"},{"key":"2122_CR2","doi-asserted-by":"crossref","unstructured":"Moch H, Amin MB, Berney DM, et al (2022) The 2022 World Health Organization classification of tumours of the urinary system and male genital organs\u2014part a: renal, penile, and testicular tumours. Eur Urol 82(5)","DOI":"10.1016\/j.eururo.2022.06.016"},{"issue":"5","key":"2122_CR3","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1007\/s11307-024-01938-6","volume":"26","author":"SP Rowe","year":"2024","unstructured":"Rowe SP, Murtazaliev S, Oldan JD et al (2024) Imaging of chromophobe renal cell carcinoma with (99m)Tc-Sestamibi SPECT\/CT: considerations regarding risk stratification and histologic reclassification. Mol Imaging Biol 26(5):768\u2013773","journal-title":"Mol Imaging Biol"},{"issue":"3","key":"2122_CR4","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.240308","volume":"314","author":"SG Silverman","year":"2025","unstructured":"Silverman SG, Pedrosa I, Schieda N, Margulis V, Kapur P, Davenport MS (2025) In pursuit of KI-RADS: toward a single, evidence-based imaging classification of renal masses. Radiology 314(3):e240308","journal-title":"Radiology"},{"issue":"1","key":"2122_CR5","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.juro.2014.07.102","volume":"193","author":"DC Johnson","year":"2015","unstructured":"Johnson DC, Vukina J, Smith AB et al (2015) Preoperatively misclassified, surgically removed benign renal masses: a systematic review of surgical series and United States population level burden estimate. J Urol 193(1):30\u201335","journal-title":"J Urol"},{"issue":"6","key":"2122_CR6","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.urology.2012.12.049","volume":"81","author":"PM Pierorazio","year":"2013","unstructured":"Pierorazio PM, Hyams ES, Tsai S et al (2013) Multiphasic enhancement patterns of small renal masses (<\/=4 cm) on preoperative computed tomography: utility for distinguishing subtypes of renal cell carcinoma, angiomyolipoma, and oncocytoma. Urology 81(6):1265\u20131271","journal-title":"Urology"},{"issue":"7","key":"2122_CR7","doi-asserted-by":"publisher","DOI":"10.1148\/rg.220209","volume":"43","author":"AS Shetty","year":"2023","unstructured":"Shetty AS, Fraum TJ, Ballard DH et al (2023) Renal mass imaging with MRI clear cell likelihood score: a user\u2019s guide. Radiographics 43(7):e220209","journal-title":"Radiographics"},{"issue":"3","key":"2122_CR8","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1148\/radiol.211680","volume":"303","author":"N Schieda","year":"2022","unstructured":"Schieda N, Davenport MS, Silverman SG et al (2022) Multicenter evaluation of multiparametric MRI clear cell likelihood scores in solid indeterminate small renal masses. Radiology 303(3):590\u2013599","journal-title":"Radiology"},{"issue":"9","key":"2122_CR9","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.diii.2024.07.003","volume":"105","author":"SP Rowe","year":"2024","unstructured":"Rowe SP, Islam MZ, Viglianti B et al (2024) Molecular imaging for non-invasive risk stratification of renal masses. Diagn Interv Imaging 105(9):305\u2013310","journal-title":"Diagn Interv Imaging"},{"issue":"3","key":"2122_CR10","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.eururo.2015.08.056","volume":"69","author":"MA Gorin","year":"2016","unstructured":"Gorin MA, Rowe SP, Baras AS et al (2016) Prospective evaluation of (99m)Tc-sestamibi SPECT\/CT for the diagnosis of renal oncocytomas and hybrid oncocytic\/chromophobe tumors. Eur Urol 69(3):413\u2013416","journal-title":"Eur Urol"},{"issue":"10","key":"2122_CR11","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/S1470-2045(24)00402-9","volume":"25","author":"B Shuch","year":"2024","unstructured":"Shuch B, Pantuck AJ, Bernhard JC et al (2024) [(89)Zr]Zr-girentuximab for PET-CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial. Lancet Oncol 25(10):1277\u20131287","journal-title":"Lancet Oncol"},{"issue":"4","key":"2122_CR12","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.euf.2020.02.010","volume":"7","author":"ZT Su","year":"2021","unstructured":"Su ZT, Patel HD, Huang MM et al (2021) Cost-effectiveness analysis of (99m)Tc-sestamibi SPECT\/CT to guide management of small renal masses. Eur Urol Focus 7(4):827\u2013834","journal-title":"Eur Urol Focus"},{"key":"2122_CR13","doi-asserted-by":"crossref","unstructured":"Silverman SG, Pedrosa I, Ellis JH, et al (2019) Bosniak classification of cystic renal masses, version 2019: an update proposal and needs assessment. Radiology 292(2)","DOI":"10.1148\/radiol.2019182646"},{"issue":"4","key":"2122_CR14","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.juro.2017.04.089","volume":"198","author":"NE Canvasser","year":"2017","unstructured":"Canvasser NE, Kay FU, Xi Y et al (2017) Diagnostic accuracy of multiparametric magnetic resonance imaging to identify clear cell renal cell carcinoma in cT1a renal masses. J Urol 198(4):780\u2013786","journal-title":"J Urol"},{"key":"2122_CR15","doi-asserted-by":"crossref","unstructured":"Duchene DA, Lotan Y, Cadeddu JA, Sagalowsky AI, Koeneman KS (2003) Histopathology of surgically managed renal tumors: analysis of a contemporary series. Urology;62(5)","DOI":"10.1016\/S0090-4295(03)00658-7"},{"key":"2122_CR16","doi-asserted-by":"crossref","unstructured":"St\u00f6rkel S, van den Berg E (1995) Morphological classification of renal cancer - PubMed. World J Urol 13(3)","DOI":"10.1007\/BF00184870"},{"key":"2122_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.786307","author":"J An","year":"2022","unstructured":"An J, Packiam VT, Chennamadhavuni A et al (2022) Patient characteristics and survival outcomes of non-metastatic, non-clear cell renal cell carcinoma. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2021.786307","journal-title":"Front Oncol"},{"key":"2122_CR18","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000016309","author":"J Deng","year":"2019","unstructured":"Deng J, Li L, Xia H et al (2019) A comparison of the prognosis of papillary and clear cell renal cell carcinoma: evidence from a meta-analysis. Medicine (Baltimore). https:\/\/doi.org\/10.1097\/MD.0000000000016309","journal-title":"Medicine (Baltimore)"},{"issue":"9","key":"2122_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0184173","volume":"12","author":"N Wagener","year":"2017","unstructured":"Wagener N, Edelmann D, Benner A et al (2017) Outcome of papillary versus clear cell renal cell carcinoma varies significantly in non-metastatic disease. PLoS ONE 12(9):e0184173","journal-title":"PLoS ONE"},{"issue":"2","key":"2122_CR20","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1148\/radiol.2018171557","volume":"287","author":"FU Kay","year":"2018","unstructured":"Kay FU, Canvasser NE, Xi Y et al (2018) Diagnostic performance and interreader agreement of a standardized MR imaging approach in the prediction of small renal mass histology. Radiology 287(2):543\u2013553","journal-title":"Radiology"},{"key":"2122_CR21","doi-asserted-by":"crossref","unstructured":"Shuch B, Hanley JM, Lai JC, et al (2014) Adverse health outcomes associated with surgical management of the small renal mass. J Urol 191(2)","DOI":"10.1016\/j.juro.2013.08.074"},{"key":"2122_CR22","doi-asserted-by":"crossref","unstructured":"Kim JH, Li S, Khandwala Y, Chung KJ, Park HK, Chung BI (2019) Association of prevalence of benign disease after partial nephrectomy with preoperative imaging patterns. JAMA Surg 154(3)","DOI":"10.1001\/jamasurg.2018.4602"},{"key":"2122_CR23","doi-asserted-by":"crossref","unstructured":"Vijay V, Vokshi FH, Smigelski M, Nagpal S, Huang WC (2023) Incidence of benign renal masses in a contemporary cohort of patients receiving partial nephrectomy for presumed renal cell carcinoma. Clin Genitourin Cancer 21(3)","DOI":"10.1016\/j.clgc.2022.11.006"},{"issue":"3","key":"2122_CR24","doi-asserted-by":"publisher","first-page":"183 e9","DOI":"10.1016\/j.urolonc.2018.11.019","volume":"37","author":"KA Nguyen","year":"2019","unstructured":"Nguyen KA, Brito J, Hsiang W et al (2019) National trends and economic impact of surgical treatment for benign kidney tumors. Urol Oncol 37(3):183 e9-e15","journal-title":"Urol Oncol"},{"key":"2122_CR25","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003433","author":"M Butaney","year":"2023","unstructured":"Butaney M, Wilder S, Patel AK et al (2023) Initial management of indeterminate renal lesions in a statewide collaborative: a MUSIC-KIDNEY analysis. J Urol. https:\/\/doi.org\/10.1097\/JU.0000000000003433","journal-title":"J Urol"},{"issue":"10351","key":"2122_CR26","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/S0140-6736(22)01059-5","volume":"400","author":"GD Stewart","year":"2022","unstructured":"Stewart GD, Klatte T, Cosmai L et al (2022) The multispeciality approach to the management of localised kidney cancer. The Lancet 400(10351):523\u201334","journal-title":"The Lancet"},{"key":"2122_CR27","doi-asserted-by":"crossref","unstructured":"Patel DN, Ghali F, Meagher MF, et al (2021) Utilization of renal mass biopsy in patients with localized renal cell carcinoma: a population-based study utilizing the National Cancer Database. Urol Oncol: Semin Orig Investig 39(1)","DOI":"10.1016\/j.urolonc.2020.10.015"},{"issue":"4","key":"2122_CR28","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.eururo.2015.07.072","volume":"69","author":"L Marconi","year":"2016","unstructured":"Marconi L, Dabestani S, Lam TB et al (2016) Systematic review and meta-analysis of diagnostic accuracy of percutaneous renal tumour biopsy. Eur Urol 69(4):660\u201373","journal-title":"Eur Urol"},{"issue":"5","key":"2122_CR29","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1111\/bju.13763","volume":"119","author":"HD Patel","year":"2017","unstructured":"Patel HD, Druskin SC, Rowe SP, Pierorazio PM, Gorin MA, Allaf ME (2017) Surgical histopathology for suspected oncocytoma on renal mass biopsy: a systematic review and meta-analysis. BJU Int 119(5):661\u20136","journal-title":"BJU Int"},{"issue":"5","key":"2122_CR30","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1007\/s11701-023-01664-1","volume":"17","author":"KE Okhawere","year":"2023","unstructured":"Okhawere KE, Pandav K, Grauer R et al (2023) Trends in the surgical management of kidney cancer by tumor stage, treatment modality, facility type, and location. J Robot Surg 17(5):2451\u201360","journal-title":"J Robot Surg"},{"key":"2122_CR31","doi-asserted-by":"crossref","unstructured":"Siva S, Louie AV, Kotecha R, et al (2024) Stereotactic body radiotherapy for primary renal cell carcinoma: a systematic review and practice guideline from the International Society of Stereotactic Radiosurgery (ISRS). Lancet Oncol 25(1)","DOI":"10.1016\/S1470-2045(23)00513-2"},{"key":"2122_CR32","doi-asserted-by":"crossref","unstructured":"Uhlig A, Uhlig J, Trojan L, Kim HS (2020) Stereotactic body radiotherapy for stage I renal cell carcinoma: national treatment trends and outcomes compared to partial nephrectomy and thermal ablation. J Vasc Interv Radiol 31(4)","DOI":"10.1016\/j.jvir.2019.11.009"},{"key":"2122_CR33","doi-asserted-by":"crossref","unstructured":"Patel AK, Rogers CG, Johnson A, et al (2021) Initial observation of a large proportion of patients presenting with clinical stage T1 renal masses: results from the MUSIC-KIDNEY Statewide Collaborative. Europ Urol Open Sci 23","DOI":"10.1016\/j.euros.2020.11.002"},{"key":"2122_CR34","doi-asserted-by":"crossref","unstructured":"Siva S, Ali M, Correa RJM, et al (2022) 5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney). Lancet Oncol 23(12)","DOI":"10.1016\/S1470-2045(22)00656-8"},{"key":"2122_CR35","doi-asserted-by":"crossref","unstructured":"Siva S, Bressel M, Sidhom M, et al (2024) Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial. Lancet Oncol 25(3)","DOI":"10.1016\/S1470-2045(24)00020-2"},{"issue":"1","key":"2122_CR36","doi-asserted-by":"publisher","first-page":"66","DOI":"10.2967\/jnumed.108.061499","volume":"51","author":"EGC Troost","year":"2010","unstructured":"Troost EGC, Schinagl DAX, Bussink J et al (2010) Innovations in radiotherapy planning of head and neck cancers: role of PET. J Nucl Med 51(1):66\u201376","journal-title":"J Nucl Med"},{"key":"2122_CR37","unstructured":"National Comprehensive Cancer Network (NCCN) (2023) Clinical Practice Guidelines in Oncology (NCCN Guidelines): Kidney Cancer. Version 1"},{"key":"2122_CR38","doi-asserted-by":"crossref","unstructured":"Nguyen KA, Nolte AC, Alimi O, et al (2019) Determinants of active surveillance in patients with small renal masses. Urology 123","DOI":"10.1016\/j.urology.2018.07.021"},{"key":"2122_CR39","doi-asserted-by":"crossref","unstructured":"Alam R, Patel HD, Osumah T, et al (2019) Comparative effectiveness of management options for patients with small renal masses: a prospective cohort study. BJU Int 123(1)","DOI":"10.1111\/bju.14490"},{"issue":"1","key":"2122_CR40","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13550-017-0329-5","volume":"7","author":"SP Rowe","year":"2017","unstructured":"Rowe SP, Gorin MA, Solnes LB et al (2017) Correlation of (99m)Tc-sestamibi uptake in renal masses with mitochondrial content and multi-drug resistance pump expression. EJNMMI Res 7(1):80","journal-title":"EJNMMI Res"},{"issue":"1","key":"2122_CR41","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/(SICI)1098-2264(199909)26:1<20::AID-GCC3>3.0.CO;2-6","volume":"26","author":"SC Clifford","year":"1999","unstructured":"Clifford SC, Walsh S, Hewson K et al (1999) Genomic organization and chromosomal localization of the human CUL2 gene and the role of von Hippel-Lindau tumor suppressor-binding protein (CUL2 and VBP1) mutation and loss in renal-cell carcinoma development. Genes Chromosomes Cancer 26(1):20\u20138","journal-title":"Genes Chromosomes Cancer"},{"key":"2122_CR42","doi-asserted-by":"crossref","unstructured":"Gormley TS, Every MJV, Moreno AJ (1996) Renal oncocytoma: preoperative diagnosis using technetium 99m sestamibi imaging. Urology 48(1)","DOI":"10.1016\/S0090-4295(96)00095-7"},{"key":"2122_CR43","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000000670","author":"SP Rowe","year":"2015","unstructured":"Rowe SP, Gorin MA, Gordetsky J et al (2015) Initial experience using 99mTc-MIBI SPECT\/CT for the differentiation of oncocytoma from renal cell carcinoma. Clin Nucl Med. https:\/\/doi.org\/10.1097\/RLU.0000000000000670","journal-title":"Clin Nucl Med"},{"issue":"8","key":"2122_CR44","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1007\/s00261-020-02469-8","volume":"45","author":"MP Wilson","year":"2020","unstructured":"Wilson MP, Katlariwala P, Murad MH, Abele J, McInnes MDF, Low G (2020) Diagnostic accuracy of 99mTc-sestamibi SPECT\/CT for detecting renal oncocytomas and other benign renal lesions: a systematic review and meta-analysis. Abdominal Radiology 45(8):2532\u201341","journal-title":"Abdominal Radiology"},{"key":"2122_CR45","doi-asserted-by":"crossref","unstructured":"Basile G, Fallara G, Verri P, et al (2024) The role of 99mTc\u2010sestamibi single-photon emission computed tomography\/computed tomography in the diagnostic pathway for renal masses: a systematic review and meta\u2010analysis. Eur Urol 85(1)","DOI":"10.1016\/j.eururo.2023.07.013"},{"key":"2122_CR46","doi-asserted-by":"crossref","unstructured":"Lobo J, Ohashi R, Amin MB, et al (2025) WHO 2022 landscape of papillary and chromophobe renal cell carcinoma. Histopathology 81(4)","DOI":"10.1111\/his.14700"},{"key":"2122_CR47","doi-asserted-by":"crossref","unstructured":"Baniak N, Flood TA, Buchanan M, Cin PD, Hirsch MS (2020) Carbonic anhydrase IX (CA9) expression in multiple renal epithelial tumour subtypes. Histopathology 77(4)","DOI":"10.1111\/his.14204"},{"issue":"6","key":"2122_CR48","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.eururo.2013.02.022","volume":"63","author":"CH Muselaers","year":"2013","unstructured":"Muselaers CH, Boerman OC, Oosterwijk E, Langenhuijsen JF, Oyen WJ, Mulders PF (2013) Indium-111-labeled girentuximab immunoSPECT as a diagnostic tool in clear cell renal cell carcinoma. Eur Urol 63(6):1101\u20136","journal-title":"Eur Urol"},{"issue":"2","key":"2122_CR49","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1200\/JCO.2011.41.2445","volume":"31","author":"CR Divgi","year":"2013","unstructured":"Divgi CR, Uzzo RG, Gatsonis C et al (2013) Positron emission tomography\/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial. J Clin Oncol 31(2):187\u201394","journal-title":"J Clin Oncol"},{"key":"2122_CR50","doi-asserted-by":"crossref","unstructured":"Shuch B, Pantuck AJ, Bernhard J-C, et al (2024) [89Zr]Zr-girentuximab for PET\u2013CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial. Lancet Oncol 25(10)","DOI":"10.1016\/S1470-2045(24)00402-9"},{"key":"2122_CR51","doi-asserted-by":"crossref","unstructured":"Ueno Y, Nogami M, Hirota K, et al (2026) Any role of FDG PET in renal cancer? Semin Nucl Med 56(2)","DOI":"10.1053\/j.semnuclmed.2025.11.006"},{"key":"2122_CR52","doi-asserted-by":"crossref","unstructured":"Liu Y (2016) The place of FDG PET\/CT in renal cell carcinoma: value and limitations. Front Oncol 6","DOI":"10.3389\/fonc.2016.00201"},{"key":"2122_CR53","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000000875","author":"M Takahashi","year":"2015","unstructured":"Takahashi M, Kume H, Koyama K et al (2015) Preoperative evaluation of renal cell carcinoma by using 18F-FDG PET\/CT. Clin Nucl Med. https:\/\/doi.org\/10.1097\/RLU.0000000000000875","journal-title":"Clin Nucl Med"},{"key":"2122_CR54","doi-asserted-by":"publisher","DOI":"10.1102\/1470-7330.2012.0042","author":"H-Y Wang","year":"2012","unstructured":"Wang H-Y, Ding H-J, Chen J-H et al (2012) Meta-analysis of the diagnostic performance of [18F]FDG-PET and PET\/CT in renal cell carcinoma. Cancer Imaging. https:\/\/doi.org\/10.1102\/1470-7330.2012.0042","journal-title":"Cancer Imaging"},{"issue":"11","key":"2122_CR55","doi-asserted-by":"publisher","first-page":"4866","DOI":"10.1007\/s00330-017-4875-z","volume":"27","author":"R Nakajima","year":"2017","unstructured":"Nakajima R, Nozaki S, Kondo T, Nagashima Y, Abe K, Sakai S (2017) Evaluation of renal cell carcinoma histological subtype and fuhrman grade using 18F-fluorodeoxyglucose-positron emission tomography\/computed tomography. Eur Radiol 27(11):4866\u201373","journal-title":"Eur Radiol"},{"issue":"2","key":"2122_CR56","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1007\/s00259-020-04996-4","volume":"48","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Wu C, Li W et al (2021) 2-[18F]FDG PET\/CT parameters associated with WHO\/ISUP grade in clear cell renal cell carcinoma. Eur J Nucl Med Mol Imaging 48(2):570\u20139","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2122_CR57","doi-asserted-by":"publisher","DOI":"10.1097\/MNM.0000000000000618","author":"H Ma","year":"2017","unstructured":"Ma H, Shen G, Liu B, Yang Y, Ren P, Kuang A (2017) Diagnostic performance of 18F-FDG PET or PET\/CT in restaging renal cell carcinoma: a systematic review and meta-analysis. Nucl Med Commun. https:\/\/doi.org\/10.1097\/MNM.0000000000000618","journal-title":"Nucl Med Commun"},{"key":"2122_CR58","doi-asserted-by":"crossref","unstructured":"Baccala A, Sercia L, Li J, Heston W, Zhou M (2007) Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms. Urology 70(2)","DOI":"10.1016\/j.urology.2007.03.025"},{"key":"2122_CR59","doi-asserted-by":"crossref","unstructured":"Sadaghiani MS, Baskaran S, Gorin MA, et al (2024) Utility of PSMA PET\/CT in staging and restaging of renal cell carcinoma: a systematic review and metaanalysis. J Nucl Med 65(7)","DOI":"10.2967\/jnumed.124.267417"},{"issue":"3","key":"2122_CR60","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1007\/s12149-024-01904-w","volume":"38","author":"T Singhal","year":"2024","unstructured":"Singhal T, Singh P, Parida GK, Agrawal K (2024) Role of PSMA-targeted PET-CT in renal cell carcinoma: a systematic review and meta-analysis. Ann Nucl Med 38(3):176\u201387","journal-title":"Ann Nucl Med"},{"key":"2122_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2023.111218","volume":"170","author":"P Aggarwal","year":"2024","unstructured":"Aggarwal P, Singh H, Das CK et al (2024) Potential role of 68Ga-PSMA PET\/CT in metastatic renal cell cancer: a prospective study. Eur J Radiol 170:111218","journal-title":"Eur J Radiol"},{"issue":"1","key":"2122_CR62","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s00259-016-3360-2","volume":"44","author":"LM Sawicki","year":"2017","unstructured":"Sawicki LM, Buchbender C, Boos J et al (2017) Diagnostic potential of PET\/CT using a 68Ga-labelled prostate-specific membrane antigen ligand in whole-body staging of renal cell carcinoma: initial experience. Eur J Nucl Med Mol Imaging 44(1):102\u20137","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2122_CR63","doi-asserted-by":"crossref","unstructured":"Al-Ahmadie HA, Olgac S, Gregor PD, et al (2008) Expression of prostate-specific membrane antigen in renal cortical tumors. Mod Pathol 21(6)","DOI":"10.1038\/modpathol.2008.42"},{"key":"2122_CR64","doi-asserted-by":"crossref","unstructured":"Pabst KM, Weber MM, Laschinsky C, et al (2025) [68Ga]Ga-FAPI-46 PET accuracy for cancer imaging with histopathology validation: a single-centre, single-arm, interventional, phase 2 trial. Lancet Oncol 26(9)","DOI":"10.1016\/S1470-2045(25)00299-2"},{"issue":"3","key":"2122_CR65","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1007\/s00259-008-0981-0","volume":"36","author":"N Oyama","year":"2009","unstructured":"Oyama N, Okazawa H, Kusukawa N et al (2009) 11C-Acetate PET imaging for renal cell carcinoma. Eur J Nucl Med Mol Imaging 36(3):422\u20137","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2122_CR66","doi-asserted-by":"crossref","unstructured":"Werner RA, Hartrampf PE, Fendler WP, et al (2023) Prostate-specific membrane antigen reporting and data system version 2.0. Eur Urol 84(5):491\u2013502","DOI":"10.1016\/j.eururo.2023.06.008"},{"key":"2122_CR67","doi-asserted-by":"crossref","unstructured":"Rao AA, Feneis J, Lalonde C, Ojeda-Fournier H (2016) A pictorial review of changes in the BI-RADS Fifth Edition. RadioGraphics 36(3):623\u201339","DOI":"10.1148\/rg.2016150178"},{"key":"2122_CR68","doi-asserted-by":"crossref","unstructured":"An JY, Unsdorfer KML, Weinreb JC (2019) BI-RADS, C-RADS, CAD-RADS, LI-RADS, Lung-RADS, NI-RADS, O-RADS, PI-RADS, TI-RADS: reporting and data systems. RadioGraphics 39(5)","DOI":"10.1148\/rg.2019190087"},{"issue":"6","key":"2122_CR69","doi-asserted-by":"publisher","DOI":"10.3390\/diseases13060167","volume":"13","author":"Z Dushimova","year":"2025","unstructured":"Dushimova Z, Iztleuov Y, Chingayeva G et al (2025) Overdiagnosis and overtreatment in prostate cancer. Diseases 13(6):167","journal-title":"Diseases"},{"key":"2122_CR70","doi-asserted-by":"crossref","unstructured":"Peng Q, Xu L, Zhang G, et al (2023) Effect of preoperative PI-RADS assessment on pathological outcomes in patients who underwent radical prostatectomy. Cancer Imag 23(1)","DOI":"10.1186\/s40644-023-00619-x"},{"key":"2122_CR71","doi-asserted-by":"crossref","unstructured":"Shaish H, Feltus W, Steinman J, Hecht E, Wenske S, Ahmed F (2018) Impact of a structured reporting template\u00a0on adherence to prostate imaging reporting and data system version\u00a02 and on the diagnostic performance of prostate MRI for clinically\u00a0significant prostate cancer. J Am Coll Radiol 15(5)","DOI":"10.1016\/j.jacr.2018.01.034"},{"key":"2122_CR72","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000466","author":"AG Singal","year":"2023","unstructured":"Singal AG, Llovet JM, Yarchoan M et al (2023) AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. https:\/\/doi.org\/10.1097\/HEP.0000000000000466","journal-title":"Hepatology"},{"key":"2122_CR73","doi-asserted-by":"crossref","unstructured":"Asi T, Tuncali M\u00c7, Tuncel M, et al (2020) The role of Tc-99m MIBI scintigraphy in clinical T1 renal mass assessment: Does it have a real benefit? Urol Oncol: Semin Orig Investig 38(12)","DOI":"10.1016\/j.urolonc.2020.07.018"},{"key":"2122_CR74","doi-asserted-by":"crossref","unstructured":"Bhindi B, Thompson RH, Lohse CM, et al (2018) The probability of aggressive versus indolent histology based on renal tumor size: implications for surveillance and treatment. Eur Urol 74(4)","DOI":"10.1016\/j.eururo.2018.06.003"},{"issue":"12","key":"2122_CR75","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.2967\/jnumed.125.271332","volume":"66","author":"SP Rowe","year":"2025","unstructured":"Rowe SP, Shuch BM, Ball MW et al (2025) SNMMI\/EANM\/ACNM procedure standard\/procedure guideline on the use of molecular imaging for renal mass characterization. J Nucl Med 66(12):1863\u20131870","journal-title":"J Nucl Med"},{"issue":"3","key":"2122_CR76","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s11307-005-4116-8","volume":"7","author":"JC Patterson","year":"2005","unstructured":"Patterson JC, Mosley ML (2005) How available is positron emission tomography in the United States? Mol Imaging Biol 7(3):197\u2013200","journal-title":"Mol Imaging Biol"},{"key":"2122_CR77","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-025-07323-x","author":"A Holzgreve","year":"2025","unstructured":"Holzgreve A, Hellwig D, Barthel H et al (2025) PET imaging utilization and trends in Germany: a comprehensive survey. Eur J Nucl Med Mol Imaging. https:\/\/doi.org\/10.1007\/s00259-025-07323-x","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"35","key":"2122_CR78","doi-asserted-by":"publisher","first-page":"56471","DOI":"10.18632\/oncotarget.10602","volume":"7","author":"I Minn","year":"2016","unstructured":"Minn I, Koo SM, Lee HS et al (2016) [64Cu]XYIMSR-06: A dual-motif CAIX ligand for PET imaging of clear cell renal cell carcinoma. Oncotarget 7(35):56471\u20139","journal-title":"Oncotarget"},{"issue":"5","key":"2122_CR79","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s11307-014-0730-7","volume":"16","author":"M Doss","year":"2014","unstructured":"Doss M, Kolb HC, Walsh JC et al (2014) Biodistribution and radiation dosimetry of the carbonic anhydrase IX imaging agent [18\u2009F]VM4-037 determined from PET\/CT scans in healthy volunteers. Mol Imaging Biol 16(5):739\u201346","journal-title":"Mol Imaging Biol"},{"key":"2122_CR80","doi-asserted-by":"crossref","unstructured":"Zhu W, Li X, Zheng G, et al (2023) Preclinical and pilot clinical evaluation of a small-molecule carbonic anhydrase IX targeting PET tracer in clear cell renal cell carcinoma. Eur J Nucl Med Mol Imaging 50(10):3116-25","DOI":"10.1007\/s00259-023-06248-7"},{"issue":"5","key":"2122_CR81","doi-asserted-by":"publisher","first-page":"740","DOI":"10.2967\/jnumed.123.267175","volume":"65","author":"MS Hofman","year":"2024","unstructured":"Hofman MS, Tran B, Feldman DR et al (2024) First-in-human safety, imaging, and dosimetry of a carbonic anhydrase IX\u2013targeting peptide, [68Ga]Ga-DPI-4452, in patients with clear cell renal cell carcinoma. J Nucl Med 65(5):740\u20133","journal-title":"J Nucl Med"},{"key":"2122_CR82","doi-asserted-by":"crossref","unstructured":"Zhu W, Huo L, Li X, et al (2025) Comparison of 68Ga-NY104 PET\/CT with 18F-FDG PET\/CT in patients with metastatic clear cell renal cell carcinoma (NYCRM): A prospective, comparative phase II study. J Clin Oncol. 43(16_suppl)","DOI":"10.1200\/JCO.2025.43.16_suppl.4524"},{"key":"2122_CR83","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000005231","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, Li L, Wang H et al (2024) Heterogeneous uptake of 68Ga-DOTATATE and 18F-FDG in initial diagnosed neuroendocrine tumors patients: which patients are suitable for dual-tracer PET imaging? Clin Nucl Med. https:\/\/doi.org\/10.1097\/RLU.0000000000005231","journal-title":"Clin Nucl Med"},{"key":"2122_CR84","doi-asserted-by":"crossref","unstructured":"Ryu J, Hyung J, Han S, et al (2024) Impact of 18F-FES PET\/CT on clinical decisions in the management of recurrent or metastatic breast cancer. J Nucl Med 65(11)","DOI":"10.2967\/jnumed.124.267913"},{"key":"2122_CR85","doi-asserted-by":"crossref","unstructured":"Chamie K, Donin NM, Kl\u00f6pfer P, et al (2017) Girentuximab following nephrectomy for high-risk renal cell carcinoma. JAMA Oncol 3(7).","DOI":"10.1001\/jamaoncol.2016.4419"},{"key":"2122_CR86","doi-asserted-by":"crossref","unstructured":"Motzer RJ, Knezevic A, Voss MH, et al (2025) STARLITE 2: Phase 2 study of nivolumab plus 177lutetium-labeled anti\u2013carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab (177Lu-girentuximab) in patients with advanced clear cell renal cell carcinoma (ccRCC). J Clin Oncol 43(16_suppl)","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS4612"},{"key":"2122_CR87","doi-asserted-by":"crossref","unstructured":"Hasanov E, Flynt L, Hwang H, et al (2024) Phase 1b\/2 study of combination 177Lu girentuximab plus cabozantinib and nivolumab in treatment naive patients with advanced clear cell RCC. J Clin Oncol 42(16_suppl)","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS4610"},{"issue":"1","key":"2122_CR88","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-067496","volume":"13","author":"H Warren","year":"2023","unstructured":"Warren H, Wagner T, Gorin MA et al (2023) Protocol for a MULTI-centre feasibility study to assess the use of 99mTc-sestaMIBI SPECT\/CT in the diagnosis of kidney tumours (MULTI-MIBI study). BMJ Open 13(1):e067496","journal-title":"BMJ Open"},{"key":"2122_CR89","doi-asserted-by":"crossref","unstructured":"Warren H, Wagner T, El-Sheikh S, et al (2025) [99mTc]Tc-sestamibi SPECT\/CT for the diagnosis of kidney tumours: a multi-centre feasibility study (MULTI-MIBI Study). Eur J Nucl Med Mol Imaging 53(3):1719-1728","DOI":"10.1007\/s00259-025-07525-3"},{"key":"2122_CR90","doi-asserted-by":"crossref","unstructured":"Rowe SP, Soyer P, Fishman EK (2022) The future of radiology: what if artificial intelligence is really as good as predicted? Diagn Interv Imaging. 103(9)","DOI":"10.1016\/j.diii.2022.04.006"},{"key":"2122_CR91","doi-asserted-by":"crossref","unstructured":"Boeken T, Feydy J, Lecler A, et al (2023) Artificial intelligence in diagnostic and interventional radiology: where are we now? Diagn Interv Imaging. 104(1)","DOI":"10.1016\/j.diii.2022.11.004"},{"issue":"10","key":"2122_CR92","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.1111\/cas.15511","volume":"113","author":"T Hayashida","year":"2022","unstructured":"Hayashida T, Odani E, Kikuchi M et al (2022) Establishment of a deep\u2010learning system to diagnose BI\u2010RADS4a or higher using breast ultrasound for clinical application. Cancer Sci 113(10):3528\u201334","journal-title":"Cancer Sci"},{"key":"2122_CR93","doi-asserted-by":"crossref","unstructured":"Laino ME, Vigan\u00f2 L, Ammirabile A, et al (2022) The added value of artificial intelligence to LI-RADS categorization: a systematic review. Eur J Radiol 150","DOI":"10.1016\/j.ejrad.2022.110251"},{"key":"2122_CR94","doi-asserted-by":"publisher","DOI":"10.1556\/1647.2025.00325","author":"AB Gavade","year":"2025","unstructured":"Gavade AB, Gavade PA, Nerli RB, Cooper DC, Sztandera L, Mehta U (2025) Artificial intelligence in prostate cancer diagnosis: a systematic review of advances in\u00a0gleason grade and PI-RADS classification. Imaging (Paris). https:\/\/doi.org\/10.1556\/1647.2025.00325","journal-title":"Imaging (Paris)"},{"key":"2122_CR95","doi-asserted-by":"crossref","unstructured":"Rowe SP, Chu LC (2025) Volumetric tumor burden and liquid biopsy metrics as emerging biomarkers in solid cancer. Diagn Interv Imaging 106(12):409-410","DOI":"10.1016\/j.diii.2025.07.005"},{"issue":"9","key":"2122_CR96","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1145\/3649447","volume":"56","author":"F Zhao","year":"2024","unstructured":"Zhao F, Zhang C, Geng B (2024) Deep multimodal data fusion. ACM Comput Surv 56(9):1\u201336","journal-title":"ACM Comput Surv"},{"key":"2122_CR97","unstructured":"Vaswani A, Shazeer N, Parmar N, et al (2017) Attention is all you need. Adv Neural Inf Process Syst 30"}],"container-title":["Molecular Imaging and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-026-02122-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11307-026-02122-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-026-02122-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T13:52:43Z","timestamp":1785505963000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11307-026-02122-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":97,"alternative-id":["2122"],"URL":"https:\/\/doi.org\/10.1007\/s11307-026-02122-8","relation":{},"ISSN":["1536-1632","1860-2002"],"issn-type":[{"value":"1536-1632","type":"print"},{"value":"1860-2002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"assertion":[{"value":"1 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No relevant competing interests were identified.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}